To examine the relationship between the use of ADT and the subsequent risk of falls in men with prostate cancer by employing a population-based dataset.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
We retrieved the study sample from the Taiwan Longitudinal Health Insurance Database 2005. We included 886 patients with prostate cancer who had received ADT as the study group, while 862 patients with prostate cancer who had not received ADT served as the comparison group. We then individually tracked each study patient for a 3-year period to identify those who subsequently received a diagnosis of a fall. We performed Cox proportional hazard regressions to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for a fall during the 3-year follow-up period between these two groups.
The incidence rates of falls per 1000 person-years were 13.37 (95% CI: 9.15~18.88) and 6.44 (95% CI: 3.61~10.63), respectively, for patients with prostate cancer who received ADT and those who did not receive ADT. Furthermore, the HR for a fall during the 3-year follow-up period for patients with prostate cancer who had received ADT was 1.95 (95% CI: 1.04~3.66, p=0.037) compared to those who had not received ADT after censoring sampled patients who died during the 3-year follow-up period and adjusting for age, geographical location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, coronary heart disease, Parkinson's disease, epilepsy, stroke, and mental illness.
The present findings suggest that patients with prostate cancer who had received ADT had an increased risk of falls.
Urology. 2016 Jun 15 [Epub ahead of print]
Fang-Jen Wu, Shiow-Yunn Sheu, Herng-Ching Lin, Shiu-Dong Chung
School of Pharmacy, Taipei Medical University, Taipei, Taiwan., School of Pharmacy, Taipei Medical University, Taipei, Taiwan., School of Medical Laboratory Sciences and Biotechnology, Taipei Medical, University, Taipei, Taiwan; Sleep Research Center, Taipei Medical University Hospital, Taipei, Taiwan., Sleep Research Center, Taipei Medical University Hospital, Taipei, Taiwan; Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Ban Ciao, Taipei, Taiwan. Electronic address: .